低氧诱导因子脯氨酰羟化酶抑制剂治疗肾性贫血的研究进展
发布时间：2018-07-29 11:41
【摘要】：慢性肾脏病(chronic kidney disease,CKD)是一种长期性进展性疾病,是以肾功能丢失逐渐加重为特征的一种疾病,甚至会导致终末期肾脏疾病,需要肾移植或者肾透析。贫血是CKD患者的常见并发症,且随肾功能下降贫血发生率不断上升。红细胞生成刺激剂(erythropoiesis stimulating agents,ESAs)是目前治疗肾性贫血的主导药物,然而,心血管安全风险限制了ESAs的应用。所以,近几年开始探索新型的红细胞生成刺激剂制剂,一种新型口服的低氧诱导因子脯氨酰羟化酶(hypoxia-inducible factor-prolyl hydroxylase,HIF-PHD)抑制剂,日益受到国内外研究人员的关注,然而系统的综述较少。鉴于此,本文将对新型的口服低氧诱导因子脯氨酰羟化酶抑制剂的作用机制及全球研究进展进行综述,重点对目前研发比较成熟进入临床阶段的药物进行综述。
[Abstract]:Chronic kidney disease (chronic kidney) is a long-term progressive disease characterized by gradual deterioration of renal function. It may even lead to end-stage renal disease requiring kidney transplantation or renal dialysis. Anemia is a common complication in patients with CKD, and the incidence of anemia increases with the decline of renal function. ESAs, a erythrocyte stimulating agent, is the leading drug in the treatment of renal anemia. However, cardiovascular safety risks limit the use of ESAs. Therefore, in recent years, researchers at home and abroad have been paying more and more attention to a new erythrocyte stimulating agent, a new type of hypoxia-inducible factor-prolyl hydroxylase HIF-PhD inhibitor, which has been systematically reviewed. In view of this, this article will review the action mechanism and global research progress of new oral hypoxia inducible factor proline hydroxylase inhibitors, focusing on the current research and development of more mature drugs into the clinical stage.
【作者单位】： 江苏德源药业股份有限公司;
【分类号】：R969.4
本文编号：2152569
[Abstract]:Chronic kidney disease (chronic kidney) is a long-term progressive disease characterized by gradual deterioration of renal function. It may even lead to end-stage renal disease requiring kidney transplantation or renal dialysis. Anemia is a common complication in patients with CKD, and the incidence of anemia increases with the decline of renal function. ESAs, a erythrocyte stimulating agent, is the leading drug in the treatment of renal anemia. However, cardiovascular safety risks limit the use of ESAs. Therefore, in recent years, researchers at home and abroad have been paying more and more attention to a new erythrocyte stimulating agent, a new type of hypoxia-inducible factor-prolyl hydroxylase HIF-PhD inhibitor, which has been systematically reviewed. In view of this, this article will review the action mechanism and global research progress of new oral hypoxia inducible factor proline hydroxylase inhibitors, focusing on the current research and development of more mature drugs into the clinical stage.
【作者单位】： 江苏德源药业股份有限公司;
【分类号】：R969.4
【相似文献】
相关期刊论文 前2条
1 孟庆林;朴翔宇;;低氧诱导因子抑制药在抗肿瘤方面的研究进展[J];医药导报;2013年07期
2 牛非;李燕;来芳芳;陈晓光;;低氧诱导因子1抑制剂的抗肿瘤研究进展[J];药学学报;2014年06期
相关会议论文 前3条
1 赵建;张连方;陈博;齐进;周琦;王晋申;钱念东;邓廉夫;;局部应用低氧诱导因子激活剂对去势小鼠骨折愈合的促进作用[A];第十八届全国中西医结合骨伤科学术研讨会论文汇编[C];2011年
2 关雅琼;盛荣;胡永洲;;低氧诱导因子HIF-1α抑制剂研究进展[A];2012长三角药物化学研讨会论文集[C];2012年
3 邹颖;王斌;倪永兵;肖继皋;张爱霞;王鹃;;低氧诱导因子1在PC12细胞化学缺氧复氧损伤中的作用[A];中国药理学会第八次全国代表大会暨全国药理学术会议论文摘要汇编[C];2002年
，本文编号：2152569
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2152569.html
最近更新
教材专著
